MarketPulse

AACR 2026

7 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Nurix Therapeutics Showcases Protein Degradation Pipeline Potential at AACR 2026

Nurix Therapeutics unveils preclinical data showing protein degradation pipeline effectiveness, with NRX-0305 achieving 142% lifespan extension in melanoma models.
PFESNYGILDNRIXdrug developmentoncology pipeline
GlobeNewswire Inc.GlobeNewswire Inc.··Immunocore Holdings Plc

KIMMTRAK Doubles Five-Year Survival in Metastatic Uveal Melanoma

Immunocore's KIMMTRAK doubled five-year survival in metastatic uveal melanoma, achieving 16% vs. 8% control rate—longest T cell engager follow-up in solid tumors.
IMCRclinical trialimmunotherapy
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Acrivon's Dual Drug Combo Shows Promise Against Cancer in Preclinical Trial

Acrivon highlights preclinical data for ACR-368 and ACR-2316 combination therapies at AACR 2026, showing synergies with checkpoint inhibitors and ADCs.
ACRVimmunotherapysynergy
GlobeNewswire Inc.GlobeNewswire Inc.··Zymeworks Inc.

Zymeworks Advances Oncology Pipeline With RAS-Targeting ADCs at AACR 2026

Zymeworks presents six ADC program updates at AACR 2026, including Phase 1 ZW191 clinical data and novel RAS-targeting platform preclinical results.
ZYMEantibody-drug conjugateoncology
GlobeNewswire Inc.GlobeNewswire Inc.··Mink Therapeutics

MiNK Therapeutics Advances iNKT Cell Therapy for Hard-to-Treat Gastric Cancer

MiNK Therapeutics will present Phase II data on agenT-797 combined immunotherapy for PD-1 refractory gastroesophageal cancer at AACR 2026.
INKTimmunotherapyPhase II trial
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Nuvectis Pharma to Showcase NXP900 Cancer Drug Data at 2026 AACR Meeting

Nuvectis Pharma will present three posters on NXP900, a first-in-class cancer inhibitor, at April's AACR Meeting in San Diego, highlighting combination and immunotherapy potential.
NVCTprecision medicineoncology
GlobeNewswire Inc.GlobeNewswire Inc.··Amphista Therapeutics

Amphista Therapeutics Showcases Next-Gen Cancer Degraders at AACR Meeting

Amphista Therapeutics presents three programs at AACR 2026, including oral presentation on AMX-883 BRD9 degrader for AML treatment.
LLYNVScancer treatmentprotein degradation